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Abstract 
Intrinsically Disordered Proteins (IDPs) play crucial roles in many important cellular processes such as 
signalling or regulation and are attractive therapeutic targets for several diseases. The considerable 
structural flexibility of IDPs poses a challenge for rational drug discovery approaches. Consequently 
structure-based drug design efforts to date have mostly focused on inhibiting interactions of IDPs with 
other proteins whose structure can be solved by conventional biophysical methods. Yet, in recent years 
several examples of small molecules that bind to monomeric IDPs in their disordered states have been 
reported, suggesting that this approach may offer new opportunities for therapeutic interventions. 
Further developments of this strategy will greatly benefit from an improved understanding of molecular 
recognition mechanisms between small molecules and IDPs. This article summarizes findings from 
experimental and computational studies of the mechanisms of interaction between small molecules and 
three IDPs in their disordered states: c-Myc, A peptide and -synuclein.  
 
* To whom correspondence should be addressed (email  julien.michel@ed.ac.uk) 
Abbreviations used: IDPs, intrinsically disordered proteins; A, Alzheimer -amyloid peptide; 
bHLHZip, basic helix-loop-helix leucine zipper; AD, Alzheimer’s disease; APP, Amyloid precursor 
protein; DA, dopamine; MD, molecular dynamics. 
Keywords: intrinsically disordered proteins, small molecules, c-Myc, -synuclein, A peptide. 
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Introduction 
The cell machinery is controlled by a large number of interactions between proteins and nucleic acids. 
It is now well appreciated that a large number of proteins do not adopt a single well defined structure 
under native conditions. Proteins that contain a segment of at least 30 consecutive disordered residues in 
their native state are typically classified as Intrinsically Disordered Proteins (IDPs) [1]. In comparison 
with globular proteins, IDPs tend to contain fewer hydrophobic residues but are generally enriched in 
charged amino acids [2-4]. IDPs can adopt a broad range of conformations, ranging from collapsed to 
fully extended. The considerable flexibility of IDPs facilitates interactions with a broad range of 
proteins and explains why IDPs often play key roles in important cellular processes such as signalling or 
transcription [5,6].
 
Molecular recognition between an IDP and a partner protein can involve a disorder-
to-order transition through a coupled folding upon binding mechanism, which produces high-specificity 
low-affinity complexes [7]. There are however several examples of IDPs that remain disordered upon 
complex formation [8]. 
 IDPs are attractive therapeutic targets as they are often implicated in a broad range of diseases such 
as cancers, cardiovascular disease or neurodegenerative diseases. However the considerable flexibility 
of IDPs presents a challenge for drug discovery approaches [9]. Due to their lack of a well-defined 
tertiary structure, it is generally not possible to determine the structure of isolated IDPs. So far structure-
based approaches to inhibiting IDPs have targeted either partner proteins that are ordered, or ordered 
complexes, in those cases where IDPs fold upon binding. For instance, the p53 tumor suppressor is an 
IDP that is involved in the progression of more than 50% of human cancers. The transcriptional activity 
of p53 is tightly regulated by partner protein MDM2 and cancer cells often over express MDM2 to 
inhibit p53 function [10]. As the p53 binding domain of MDM2 is folded, crystal structures can be 
readily obtained and have been exploited to design several classes of small molecule inhibitors of 
p53/MDM2 [11]. Some of the most successful inhibitors have advanced in clinical trials [12]. 
However several protein-protein interactions involve two IDPs whose structure cannot be solved in 
isolation. Even in those instances where two IDPs mutually fold upon binding, the structure of the 
complex may not reveal pockets that small molecules could readily bind to. Thus a more general route 
to inhibiting IDP function would be to directly target their disordered state with small molecules. 
Historically, this approach has not been considered feasible [13]. However this view has been 
challenged in recent years, with the discovery of several small molecules that inhibit IDP function by 
binding to their unfolded state [14-16]. The interactions of small molecules with IDPs challenge our 
understanding of molecular recognition and it is important to clarify the mechanisms of IDP-small 
molecule interactions before such proteins can be more routinely targeted. This review article focuses 
on three well-studied systems, the oncoprotein c-Myc, the Alzheimer -amyloid peptide (A) and -
synuclein. 
 
c-Myc 
 
The proto-oncogene protein c-Myc is constituted of 439 amino acids and contains an 88 amino acids 
basic helix-loop-helix leucine zipper (bHLHZip) domain. In its monomeric form, c-Myc is intrinsically 
disordered. c-Myc has been shown to interact with a large number of other proteins. The specific 
interaction between c-Myc and the protein Max has been studied extensively because the c-Myc/Max  
heterodimer binds DNA and regulate gene expressions [17]. It has been shown that overexpression of c-
Myc is frequent in many cancers, and disruption of the c-Myc/Max interaction is a possible anticancer 
strategy [5].  
Structurally diverse small molecules inhibiting the formation of this complex were discovered through 
a yeast-two hybrid screen [14]. Biophysical studies using fluorescence assays, NMR and circular 
dichroism measurements were performed to characterize protein-ligand interactions [18-20]. These 
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studies suggest that the small molecules disrupt the c-Myc/Max interaction by stabilizing conformations 
in monomeric c-Myc that are incompatible with heterodimerization with Max. Three distinct binding 
sites, encompassing residues 366-375, 375-385 and 402-409, have been mapped on the c-Myc bHLHZip 
domain [18]. Remarkably, the three distinct c-Myc binding sites can be occupied simultaneously by 
different ligands. These results suggest that the c-Myc/small molecules interactions are fairly localized 
and can be predicted from primary sequence analysis. Indeed, protein disorder prediction algorithms can 
locate approximately the c-Myc small molecule binding sites, which tend to be enriched in hydrophobic 
amino-acids in comparison with the rest of the domain [20]. In addition, many of the small molecule 
ligands can bind truncated c-Myc segments containing a single binding site with a binding affinity 
similar to the full c-Myc bHLHPZip domain. For instance, the small molecule 10058-F4 binds in a 
fluorescence polarisation assay c-Myc353-437 with a Kd of 5.3 ± 0.7 µM  and c-Myc402-412 with a Kd of 
13.3 ± 1 µM [20]. Furthermore, similar chemical shift perturbations were observed for c-Myc353-437 and 
c-Myc402-412 upon binding 10058-F4.  NMR and circular dichroism studies suggest that c-Myc remains 
disordered upon binding 10058-F4. Ligand binding appears to lead to formation of a hydrophobic 
cluster between the ligand and the side-chains of Tyr
402
, Ile
403
, Leu
404
 and Val
406
 (Figure 1). Molecular 
dynamics studies performed in our group reveals multiple distinct binding modes for 10058-F4, with 
frequent stacking interactions with Tyr
402
 as well as hydrogen-bonding interactions of with the main 
chain of Tyr
402
, Val
406
 and Lys
412
 (Unpublished work, J Michel and R Cuchillo). 
 
Alzheimer β-amyloid peptide  
 
Alzheimer disease (AD) is a neurodegenerative pathology characterized by the formation of senile 
plaques into the brain [21]. The aggregation of A, also called Amyloid  peptide, is known to be one of 
the main components of those plaques and may be associated with the pathogenesis of AD [22,23]. A  
(36-43 amino acids) is produced by the successive cleavage of the amyloid precursor protein (APP) by 
the enzymes -secretase and γ-secretase. Although the role of APP is not completely characterized, it 
appears to be crucial for synapse formation and function [24]. The aggregation of this small peptide, as 
well as with other compounds such as apoliprotein E, induces the development of senile plaques. The 
A peptide adopts a folded helical structure in membrane environments, but an aggregation prone -
sheet conformation in aqueous solution [25]. 
During the last decades, many peptide and small molecule inhibitors of Aβ aggregation have been 
discovered, primarily through in vitro assays [26]. Current small molecules inhibitors appear to inhibit 
Aaggregation through at least two distinct mechanisms. For instance scyllo-inositol derivatives have 
been shown by electron microscopy experiments to bind and stabilize monomeric and trimeric forms, 
thus blocking aggregation [27,28].
 
On the other hand compounds like Thioflavin T or Congo red appear 
to interact with  A peptide aggregates, although decades of studies on these compounds have produced 
several conflicting models describing binding mechanisms. Groening has recently reviewed extensively 
plausible hypotheses [29]. 
Computational studies have attempted to clarify protein-ligand interactions. Molecular dynamics 
simulations were recently performed for ten small molecule inhibitors in presence of a truncated Aβ 
(A12-28) [30]. Although the small molecules did not exhibit a predominant binding modes and did not 
dramatically affect the secondary structure preferences of A12-28, a number of conserved interactions 
with Aβ12-28 could be observed. Most of the ligands interacted preferentially with the N-terminal portion 
of the peptide (residues 13-20). Energetic analysis revealed favorable electrostatic interactions with 
several charged amino acids (His
13
, His
14
, Lys
16
). Additionally, favorable hydrophobic interactions are 
observed between the inhibitors and the entire N-terminals stretch, the sites of highest interaction 
probability are near the side chains of Phe
19
 and Phe
20
. The binding affinities appear to be  roughly 
correlated with the number of aromatic groups and charged groups present in the ligands. MD 
simulations have also been performed to examine the interactions of two small molecules, Pep1b and 
Dec-DETA that were designed to stabilize the central helix in the A peptide [31]. Both ligands appear 
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to stabilize the A central helix (residues 15-24) in A13-26 by interacting preferentially with two 
charged amino acids, Glu
22
 and Asp
23
.  In addition, electrostatic interactions with His
13
, Lys
16
 as well as 
hydrophobic interactions with Phe
19
 and Phe
20
 were also reported for Pep1b (Figure 1). It appears that 
the extended side-chains interactions between the small molecules and the A peptide disfavor 
intramolecular side-chain interactions that would destabilize the central -helix. Recently, molecular 
dynamics simulations were used to study the interactions of inositol ligands with (Gly-Ala)4  modelled 
either as small disordered or b-sheet aggregates of 4 peptides, or an extended fibril like oligomer. The 
ligands were observed to form predominantly mono-dentate and bi-dentate hydrogen bonds with the 
peptide backbone. The results suggested that inositol does not inhibit amyloid formation by dispersing 
preformed aggregates, but more likely binds to the surface of prefibrillar aggregates. The computed 
dissociation constants of the ligands were much higher than the observed in vitro inhibitory 
concentrations of A peptide aggregation, suggesting the existence of important side-chain interactions 
with  A peptide aggregates. [32]. 
 
α-synuclein  
 
The 140 amino acids protein -synuclein is constituted of three distinct domains. The central region 
of -synuclein is known to be crucial for the aggregation of -synuclein fibrils, one of the main 
component of Lewy bodies associated with many neurodegenerative diseases such as Parkinson’s 
Disease (PD) [33,34]. Under physiological conditions, -synuclein normally adopts an helical 
conformation that is non-pathogenic and plays a role in neurotransmitter release. It is still not well 
understood how -synuclein first forms soluble oligomers called protofibrils, followed by the 
development of β-sheet rich -synuclein fibrils. In light of these observations, a deeper molecular-level 
understanding of interactions between monomeric, protofibril and fibril forms is important to facilitate 
the discovery of small molecules inhibitors of -synuclein fibrillization.  
A few years ago, fifteen fibrillization inhibitors were found by screening a small molecule library 
using a fibrillization assay [35]. Many of these inhibitors are members of the catecholamine family and 
include Dopamine (DA). There is controversy about the mechanisms of interactions between DA and  
-synuclein. Conway et al. have suggested that DA readily oxidizes into dopamine-derive orthoquinone 
(DAQ) that subsequently form a covalent adduct with -synuclein by radical coupling to form 
dityrosine linkages or nucleophilic attack of a lysine side chain [35]. On the other hand Norris et al. 
failed to detect significant levels of DA-syn- adducts and suggested instead that binding occurs 
through non covalent interactions with the -synuclein segment 125Tyr-Glu-Met-Pro-Ser129 [36]. Herrera 
et al. used docking calculations and molecular dynamics simulations to study the interactions of 
dopamine and several plausible oxidised derivatives with an NMR derived structural ensemble of -
synuclein. In the majority of the simulated complexes, the ligands interacted through a broad range of 
hydrogen bonding and hydrophobic interactions with the region 
125
Tyr-Glu-Met-Pro-Ser
129
. 
Additionally, large electrostatic interactions were computed between the ligands and residue Glu
83
 
located in the non--amyloid region of -synuclein. Point mutations to Ala residues in the 125YEMPS129 
region did not prevent DA inhibition of -synuclein aggregation, suggesting that DA interacts non 
specifically with this region. On the other hand, mutation of Glu
83
 to Ala  strongly impaired the ability 
of DA to inhibit a-synuclein aggregation. [37]. 
Non catecholamine inhibitors of -synuclein have also been identified. A broad range of biophysical 
methods were used by Lendel et al. to characterize the interactions of Congo red and Lacmoid with -
synuclein. They concluded that these two small molecules interact broadly with the N-terminal and 
central region of -synuclein as small oligomeric species [38].  
 
Discussion    
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Although small molecules have now been found to interact directly with several IDPs in their 
monomeric form, an important challenge is to clarify the specificity of the interactions. For instance, 
there are numerous proteins that contain a bHLHZip domain similar to c-Myc. Consequently, several 
small molecule that inhibit the c-Myc-Max complex also inhibit related bHLHZip pairs. To illustrate, 
the compound 10058-F4 has also been shown in a yeast two hybrid assay to disrupt the complexes 
MyoD-E2-2, Mad1-Max and Mxi1-Max, although several other bHLHZip pairs were not inhibited [14]. 
Several of the Dopamine derivates that inhibit -synuclein aggregation have also been shown to also 
dissolve fibrils of the A peptide in vitro [39]. Congo red and Lactoin bind readily to -synuclein, a 
protein closely related to -synuclein which does not aggregate under physiological conditions [38]. 
In several cases, relatively structurally diverse small molecules have been found to interact with  
similar regions in an IDP. Additionally, many studies suggest that the complexes between small 
molecules and IDPs remain disordered [40].
 
This suggests that the binding of the small molecules is 
driven by a large number of weak interactions [13]. Arguably, unlike proteins, small molecules are 
unlikely to induce IDP folding upon binding, as the relatively limited intermolecular contacts they form 
are unlikely to overcome the large conformational entropy loss necessary to structure an IDP. Structure-
based approaches to design ligands for IDPs will therefore have to explicitly consider multiple binding 
modes.  
Although the mechanisms of IDP aggregation are still not well understood, a number of small 
molecule inhibitors of IDP aggregation have reached clinical studies. For instance, methylthionium 
chloride, initially developed as an antimalarial agent, has been shown to inhibit in vitro the aggregation 
of the IDP tau [41]. Results of a phase II clinical trial reported that methylthionium chloride slows down 
cognitive impairment in patient suffering from AD, thus  inhibiting the formation of tau aggregates is a 
promising strategy for the development of AD treatments [42].  
 
Funding 
J.M. is supported by a Royal Society University Research Fellowship. This research was also part 
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Figure legend 
 
 
 
Figure 1. Summary of the main interactions observed in three IDP/ligand complexes, c-Myc/10058-F4, 
-synuclein/Dopamine and Amyloid  peptide/Pep1b.  
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